OOIR: Observatory of International Research

Papers

(The TQCC of Journal of Pharmacokinetics and Pharmacodynamics is 5. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-08-01 to 2025-08-01.)

Article	Citations
Application of different approaches to generate virtual patient populations for the quantitative systems pharmacology model of erythropoiesis	48
Population pharmacokinetic and pharmacodynamic model of propofol externally validated in Korean elderly subjects	47
Translational physiologically-based pharmacokinetic model for ocular disposition of monoclonal antibodies	33
Development of PBPK model for intra-articular injection in human: methotrexate solution and rheumatoid arthritis case study	27
Advancing inclusive healthcare through PBPK modelling: predicting the impact of CYP genotypes and enzyme ontogenies on infant exposures of venlafaxine and its active metabolite O-desmethylvenlafaxine	22
Learning pharmacometric covariate model structures with symbolic regression networks	21
Achieving big with small: quantitative clinical pharmacology tools for drug development in pediatric rare diseases	16
Convolution-based approach for modeling the paliperidone extended release and Long-Acting Injectable (LAI) PK of once-, and three-monthly products administration and for optimizing the development of	16
Model-informed approach to estimate treatment effect in placebo-controlled clinical trials using an artificial intelligence-based propensity weighting methodology to account for non-specific responses	15
Characterization of exposure–Clinical Dementia Rating–Sum of Boxes relationship in subjects with early Alzheimer’s disease from the aducanumab Phase 3 trials	14
Semi-mechanistic modeling of resistance development to β-lactam and β-lactamase-inhibitor combinations	14
Correction: Model-based comparison of subcutaneous versus sublingual apomorphine administration in the treatment of motor fluctuations in Parkinson’s disease	13
Translational population target binding model for the anti-FcRn fragment antibody efgartigimod	13
Mixed effect estimation in deep compartment models: Variational methods outperform first-order approximations	13
Training the next generation of pharmacometric modelers: a multisector perspective	12
Current practices for QSP model assessment: an IQ consortium survey	12
Experimental and computational assessment of the synergistic pharmacodynamic drug–drug interactions of a triple combination therapy in refractory HER2-positive breast cancer cells	11
Comparison of the power and type 1 error of total score models for drug effect detection in clinical trials	11
Oral docetaxel plus encequidar – A pharmacokinetic model and evaluation against IV docetaxel	11
Informatics for toxicokinetics	11
Population pharmacokinetics and pharmacodynamics of efmarodocokin alfa (IL-22Fc)	10
Imputation of missing clock times – application to procalcitonin concentration time course after birth	10
Generative models for synthetic data generation: application to pharmacokinetic/pharmacodynamic data	10
Comparison of monoclonal antibody disposition predictions using different physiologically based pharmacokinetic modelling platforms	9
Inferring pulmonary exposure based on clinical PK data: accuracy and precision of model-based deconvolution methods	9

A system pharmacology Boolean network model for the TLR4-mediated inflammatory response in early sepsis	9
Mechanistic inference of the metabolic rates underlying $$^{13}$$C breath test curves	9
Translational pharmacokinetic and pharmacodynamic modelling of the anti-ADAMTS-5 NANOBODY® (M6495) using the neo-epitope ARGS as a biomarker	8
Latent variable indirect response modeling of clinical efficacy endpoints with combination therapy: application to guselkumab and golimumab in patients with ulcerative colitis	8
Expansion of platform physiologically-based pharmacokinetic model for monoclonal antibodies towards different preclinical species: cats, sheep, and dogs	8
Application of model-informed drug development (MIDD) for dose selection in regulatory submissions for drug approval in Japan	8
Statistical analysis of one-compartment pharmacokinetic models with drug adherence	7
A translational physiologically-based pharmacokinetic model for MMAE-based antibody-drug conjugates	7
Longitudinal modeling of efficacy response in patients with lupus nephritis receiving belimumab	7
Five multivariate Duchenne muscular dystrophy progression models bridging six-minute walk distance and MRI relaxometry of leg muscles	7
Maximum a posteriori Bayesian methods out-perform non-compartmental analysis for busulfan precision dosing	7
From complex data to biological insight: ‘DEKER’ feature selection and network inference	7
Leveraging large language models in pharmacometrics: evaluation of NONMEM output interpretation and simulation capabilities	7
Exploring Inductive Linearization for simulation and estimation with an application to the Michaelis–Menten model	7
Population pharmacokinetics of the dual endothelin receptor antagonist aprocitentan in subjects with or without essential or resistant hypertension	7
Thanks to our Reviewers of 2022!	7
A Bayesian population physiologically based pharmacokinetic absorption modeling approach to support generic drug development: application to bupropion hydrochloride oral dosage forms	7
A quantitative systems pharmacology model of plasma kallikrein-kinin system dysregulation in hereditary angioedema	6
Stochastic pharmacodynamics of a heterogeneous tumour-cell population	6
The impact of misspecified covariate models on inclusion and omission bias when using fixed effects and full random effects models	6
Correction to: Characterization of exposure–Clinical Dementia Rating–Sum of Boxes relationship in subjects with early Alzheimer’s disease from the aducanumab Phase 3 trials	6
Population pharmacokinetic/pharmacodynamic modeling of nifekalant injection with varies dosing plan in Chinese volunteers: a randomized, blind, placebo-controlled study	6
A quantitative modeling framework to understand the physiology of the hypothalamic-pituitary-adrenal axis and interaction with cortisol replacement therapy	6
Correction to: R-praziquantel integrated population pharmacokinetics in preschool- and school-aged African children infected with Schistosoma mansoni and S. haematobium and Lao adults infected with Op	6
PBPK model for antibody disposition in mouse brain: validation using large-pore microdialysis data	6
Sampling from covariate distribution may not always be necessary in PK/PD simulations: illustrative examples with antibiotics	6
Advancing cancer drug development with mechanistic mathematical modeling: bridging the gap between theory and practice	6
Application of machine learning based methods in exposure–response analysis	5
Global sensitivity analysis in physiologically-based pharmacokinetic/pharmacodynamic models of inhaled and opioids anesthetics and its application to generate virtual populations	5
Development of a genetic algorithm and NONMEM workbench for automating and improving population pharmacokinetic/pharmacodynamic model selection	5
Physiologically-based pharmacokinetic modeling to predict drug-drug interaction of enzalutamide with combined P-gp and CYP3A substrates	5
ChatGPT and Gemini large language models for pharmacometrics with NONMEM: comment	5
A physiologically-based quantitative systems pharmacology model for mechanistic understanding of the response to alogliptin and its application in patients with renal impairment	5
Correction to: Classical structural identifiability methodology applied to low-dimensional dynamic systems in receptor theory	5
A quantitative systems pharmacology model of plasma potassium regulation by the kidney and aldosterone	5
JPKPD October Special Issue - Commentary	5
Subgroup identification-based model selection to improve the predictive performance of individualized dosing	5